AB Science announces the validation of its Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France
July 12, 2021 02:00 ET | AB Science
                                                                                                                                                                                                       ...
AB Science annonce la validation de son plan de gestion des risques par l'ANSM en vue de la reprise des inclusions en France
July 12, 2021 02:00 ET | AB Science
                                                                                                                                                                                           COMMUNIQUE DE...
Isracann BioSciences Logo RGB@4x-100 LG.jpg
Isracann Increases Focus on EU Demand
May 14, 2020 00:05 ET | Isracann Biosciences Inc.
VANCOUVER, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on...
Altasciences_Gradient_V_RGB.png
Altasciences完成Gimsilumab用于新冠肺炎(COVID-19)患者ARDS的一期研究
March 28, 2020 06:57 ET | Altasciences Company Inc.
魁北克拉瓦尔, March 28, 2020 (GLOBE NEWSWIRE) --...
Altasciences_Gradient_V_RGB.png
Altasciences Completes Phase I Study on Gimsilumab for ARDS in COVID-19
March 27, 2020 13:48 ET | Altasciences Company Inc.
LAVAL, Quebec, March 27, 2020 (GLOBE NEWSWIRE) -- Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage...
WPD Pharmaceuticals Provides 2019 Corporate Year End Review
January 08, 2020 03:05 ET | WPD Pharmaceuticals
VANCOUVER, British Columbia, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Westcot Ventures Corp. (CSE: WBIO) (the “Company”), and its wholly-owned subsidiary WPD Pharmaceuticals sp. z.o.o (“WPD”), a clinical...
logo_new.jpg
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
June 04, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
May 09, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
October 03, 2018 01:00 ET | ObsEva SA
Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety profile not different from placebo in IMPLANT 2 European MAA submission...
Celixir announces US FDA approval of the IND application for cell therapy Heartcel
June 08, 2018 02:00 ET | CELIXIR Plc
Celixir announces US FDA approval of the IND application for cell therapy HeartcelTM FDA IND and UK MHRA CTA approval both achieved in H1 2018 Potentially pivotal heart failure trial of up to 250...